Inogen Inc Stock Price, News & Analysis

Inogen, a medical technology company, reported a 15.3% year-over-year revenue growth for Q4 2022, totaling $88.1 million, driven by increased rental revenue and business-to-business sales. However, the company faced a GAAP net loss of $56.6 million due to a one-time loss related to an intangible asset. For the full year 2022, total revenue rose 5.4% to $377.2 million, but GAAP net losses expanded to $83.8 million. Operating expenses surged 42.8% year-over-year, reflecting strategic investments. Despite challenges, Inogen aims to focus on its innovation pipeline for future growth.

Inogen, Inc. (Nasdaq: INGN) has achieved significant regulatory milestones, including EU MDR certification and FDA 510(k) clearance for its portable oxygen concentrators. The EU certification allows Inogen to market the Inogen One G4 and G5 in Europe, while the FDA clearance for the new Rove 4 model enhances its U.S. product lineup. The Rove 6 has already launched in Europe, with plans for the Rove 4 release in the U.S. in late 2023. These advancements affirm Inogen’s commitment to innovation in respiratory care for patients requiring oxygen therapy.

Inogen, Inc. (Nasdaq: INGN) has released preliminary revenue estimates for Q4 and full year 2022, projecting revenues between $87.5 million to $88.5 million for Q4, reflecting a year-over-year growth of 14.5% to 15.8%. For the full year, revenue estimates range from $376.7 million to $377.7 million, a growth of 5.2% to 5.5%. CEO Nabil Shabshab mentioned improved productivity as the DTC team's tenure increases, despite macroeconomic challenges. A conference call is scheduled for February 23, 2023, to discuss the financial results.

Inogen, Inc. (NASDAQ: INGN), a medical technology company specializing in respiratory products, has announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. President and CEO Nabil Shabshab will present on January 11, 2023, at 10:30 a.m. PT. A live webcast of the presentation will be available on the Inogen Investor Relations website, where archived recordings can also be accessed. Inogen is known for its innovative portable oxygen concentrators designed for patients with chronic respiratory conditions.

Inogen, Inc. (NASDAQ: INGN) has announced participation in two upcoming investor conferences. Management will present at the Stifel 2022 Healthcare Conference on November 15 at 10:20 a.m. ET and the Piper Sandler 34th Annual Healthcare Conference on November 30 at 11:30 a.m. ET. A live webcast and archived recordings of both events will be accessible through the company’s Investor Relations website. Inogen specializes in homecare respiratory products, particularly portable oxygen concentrators.

Inogen reported a total revenue of $105.4 million for Q3 2022, marking a 13.2% increase year-over-year compared to $93.1 million in Q3 2021. On a constant currency basis, revenue growth was 14.5%. However, the company faced a GAAP net loss of $9.5 million and an adjusted net loss of $4.1 million. Total operating expenses rose 28.5% to $53.1 million. Despite these challenges, Inogen maintains a robust cash position of $209.6 million with no debt. For Q4 2022, revenue guidance is projected between $87 million and $92 million, indicating a potential growth of 14% to 20%.

Inogen, Inc. (NASDAQ: INGN), a medical technology company specializing in homecare respiratory products, will announce its third quarter 2022 financial results on November 2, 2022, before the market opens. A conference call is scheduled for 5:30 am PT / 8:30 am ET on the same day, accessible via US domestic and international dialing. Investors can also tune in to a live webcast on Inogen's Investor Relations website. A replay will be available after the call until November 16, 2022, using the provided contact details.

Inogen, a medical technology company, reported total revenue of $103.4 million for Q2 2022, an increase of 1.8% year-over-year. On a constant currency basis, revenue rose 3.6%. The company experienced a net loss of $3.4 million, contrasting with a net income of $5.1 million in Q2 2021. Despite challenges, Inogen maintains a strong cash position of $223.6 million. For Q3 2022, revenue guidance is projected between $97 million and $100 million, reflecting a potential growth of 4% to 7% year-over-year.

Inogen, Inc. (Nasdaq: INGN) announced it will release its second quarter 2022 financial results on August 4, 2022. A conference call will be held at 2:00 pm PT/5:00 pm ET for discussion of the results. US callers can dial (877) 841-3961, while international callers should use (201) 689-8589. The call will also be available as a replay starting August 4, 2022, at 4:00 pm PT to August 18, 2022. Inogen specializes in innovative respiratory products, particularly portable oxygen concentrators for chronic respiratory conditions.